On April 19, 22 analysts tracked UNH stock. According to this Reuters survey, 50.0% of these analysts recommended UNH stock as a “strong buy,” and the remaining 50.0% of these analysts rated the company a “buy.” There were no “hold” or “sell” recommendations given to UNH stock.
On April 19, the analysts’ 12-month target price for UNH stock was $277.35 per share, implying a 12-month return potential of ~17.6%. The potential 12-month return is based on the stock’s closing price of $236.40 on April 18.
On April 19, these analysts’ target prices for Anthem (ANTM), CVS Health (CVS), and Aetna (AET) were $279.61, $88.19, and $205.13, respectively. These targets represent potential returns of ~22.8%, ~33.9%, and ~16.3%, respectively, for the next 12 months.
Recommendation revisions and updates
After UnitedHealth Group released its 1Q18 earnings results on April 17, several investment research firms updated their recommendations on UNH stock. On that day, Morgan Stanley raised its target price on UNH stock from $275.00 to $277.00 while maintaining its “overweight” rating on the stock.
On April 18, Credit Suisse, Piper Jaffray, Oppenheimer, Citigroup, Leerink Partners, and RBC also raised their target prices on UNH stock.